Evidence map›Paper›PMID 26405615›Full record

ArticleAndrology : open access2015

Treatment with a combination of ginger, L-citrulline, muira puama and Paullinia cupana can reverse the progression of corporal smooth muscle loss, fibrosis and veno-occlusive dysfunction in the aging rat.

Monica G Ferrini, Su M Hlaing, Andre Chan, Jorge N Artaza

Open access · hybridAbstract read
In one paragraph

Article in Andrology : open access, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Role of Nutraceuticals in Treating Erectile DysfunctionCurrent pharmaceutical biotechnology · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Safety and efficacy of daily RevactinTranslational andrology and urology · 2018
    Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Monica G FerriniDepartment of Internal Medicine, Charles R. Drew University of Medicine & Science, Los Angeles, CA 90059; Department of Health and Life Sciences, College of Science and Health, Charles R. Drew University of Medicine & Science, Los Angeles, CA 90059.
Su M HlaingDepartment of Internal Medicine, Charles R. Drew University of Medicine & Science, Los Angeles, CA 90059.
Andre ChanDepartment of Health and Life Sciences, College of Science and Health, Charles R. Drew University of Medicine & Science, Los Angeles, CA 90059.
Jorge N ArtazaDepartment of Internal Medicine, Charles R. Drew University of Medicine & Science, Los Angeles, CA 90059; Department of Health and Life Sciences, College of Science and Health, Charles R. Drew University of Medicine & Science, Los Angeles, CA 90059.
Charles R. Drew University of Medicine and Science · US

Funding

Sustaining Faculty Development & Community EngagementS21MD000103 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI CARLISLE, DAVID M · 2001 to 2015
$73.9M
Workshop for Junior Biostatisticians in Health ResearchU54MD007598 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI Ali Andalibi, Jose A Torres-Ruiz · 2012 to 2026
$60.0M
Nitric Oxide/cGMP Modulation of Corporal Fibrosis Caused by NeuropraxiaSC1NS064611 · NINDS · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI FERRINI, MONICA GABRIELA · 2008 to 2012
$1.4M
NIMHD NIH HHS S21 MD000103NIMHD NIH HHS U54 MD007598NINDS NIH HHS SC1 NS064611
6 · The paper itself

Abstract

aimsAging associated erectile dysfunction is characterized within the corpora by a progressive apoptosis of the smooth muscle cells and their replacement by collagen. Nitric oxide from iNOS has been shown to inhibit these histological changes in the corpora while PDE5 inhibitors as well as certain nutraceuticals such as ginger, paullinia cupana, muira puama and L-citrulline are known to enhance the effects of NO. We evaluated whether the daily oral administration for 2 months with a combination of ginger, paullinia cupana, muira puama and L-citrulline (COMP-4) can effectively delay the ongoing corporal fibrosis, smooth muscle cell apoptosis and cavernosal veno-occlusive dysfunction (CVOD) seen in middle aged rats similar to that seen with tadalafil.

methods10 Month old Fisher 344 rats were treated or not for two months with COMP-4, tadalafil or a combination of tadalafil plus COMP-4. CVOD was determined by dynamic infusion cavernosometry. Penile sections of the corpora cavernosa were subjected to Masson trichrome staining to evaluate fibrosis and immunohistochemistry for desmin as a marker of smooth muscle content and inducible nitric oxide synthase (iNOS) followed by image analysis. Oxidative stress levels were determined by GSH/GSSG ratio in whole blood.

resultsa decline in the non-treated rat's erectile function is evident by 10-12 months of age and is accompanied by a decrease in the corporal smooth muscle content determined by desmin expression and an increase in corporal fibrosis. The daily treatment for two months with COMP-4 reverses this process by reducing systemic oxidative stress and increasing desmin and iNOS expression, similar to that seen with tadalafil or the combination of COMP-4 plus tadalafil.

conclusionAn oral combination of ginger, muira puama, Paullinia cupana and L-citrulline seems to be as effective as daily PDE5 inhibitor therapy in either delaying or reversing the onset of the histological and functional characteristics of aging related erectile dysfunction.

Indexed as

corporal fibrosiscorporal veno-occlusive dysfunctionGingerL-Citrulline corporal smooth muscleMuira PuamaPaullinia cupana

Identifiers

PMID26405615
PMCPMC4578663
OpenAlexW2402419209

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.